Hitachi forms strategic research collaboration with Mass General Brigham in the field of regenerative medicine and GCT
By working with BWH researchers at the Mass General Brigham Gene and Cell Therapy Institute (GCTI), Hitachi will support the development of cellular models relating to various diseases.
- By working with BWH researchers at the Mass General Brigham Gene and Cell Therapy Institute (GCTI), Hitachi will support the development of cellular models relating to various diseases.
- Hitachi will also contribute to the advancement of GCT through cell culturing and the development of the culturing process required in GCT by bringing research achievements and business experience in the field of regenerative medicine and GCT.
- Mass General Brigham is a world-leading eco-system for GCT research and clinical trials, with over 400 researchers working on ground-breaking gene and cell therapy research and treatment in pursuit of potential cures.
- From an early stage, Mass General Brigham has been actively engaged in GCT research, creating GCTI in December 2022.